Topic Hub
33 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 33 of 33 clinical reviews.
Head-to-head comparison of Farxiga (dapagliflozin) and Lantus (insulin glargine) covering cost, insurance access, clinical trial outcomes, and prescribing considerations for blood sugar management.
Read clinical reviewClinical comparison of dapagliflozin (Farxiga) and insulin glargine (Lantus) for blood sugar control, cardiovascular outcomes, and weight effects. Evidence from DAPA-HF, ORIGIN, and major trials.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and insulin glargine (Lantus) side effects, including hypoglycemia risk, genital infections, weight changes, and cardiovascular safety data from DAPA-HF and ORIGIN.
Read clinical reviewClinical comparison of Farxiga (dapagliflozin) and Lantus (insulin glargine) for type 2 diabetes, including when and how to switch between them safely.
Read clinical reviewEvidence-based comparison of dapagliflozin (Farxiga) and metformin for type 2 diabetes, covering HbA1c reduction, cardiovascular outcomes, weight loss, and renal protection from landmark trials.
Read clinical reviewA clinical comparison of Farxiga (dapagliflozin) and metformin for type 2 diabetes, including when and how to switch between them, trial data, side effects, and prescriber guidance.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) for blood sugar control, cardiovascular outcomes, and weight effects, with trial data from DAPA-HF and DEVOTE.
Read clinical reviewA clinical comparison of dapagliflozin (Farxiga) and insulin degludec (Tresiba) side effects, including hypoglycemia risk, genital infections, DKA, weight changes, and cardiovascular safety data from DAPA-HF and DEVOTE.
Read clinical reviewClinical comparison of Farxiga (dapagliflozin) and Tresiba (insulin degludec), including when and how to switch between them, trial evidence from DAPA-HF and DEVOTE, and practical guidance for patients with type 2 diabetes.
Read clinical reviewA detailed comparison of side-effect profiles for Jardiance (empagliflozin) and Farxiga (dapagliflozin), including genital infections, DKA risk, cardiovascular safety, and renal effects drawn from major clinical trials.
Read clinical reviewA detailed comparison of Jardiance (empagliflozin) and Farxiga (dapagliflozin) covering pricing, insurance coverage, patient assistance programs, and clinical evidence to help you choose the right SGLT2 inhibitor.
Read clinical reviewEvidence-based comparison of Jardiance (empagliflozin) and Farxiga (dapagliflozin), including when and how to switch between SGLT2 inhibitors safely.
Read clinical reviewA clinical comparison of Jardiance (empagliflozin) and Lantus (insulin glargine) across HbA1c reduction, cardiovascular outcomes, weight effects, and hypoglycemia risk in type 2 diabetes.
Read clinical reviewClinical comparison of Jardiance (empagliflozin) and Lantus (insulin glargine) for type 2 diabetes, including when and how to switch between them safely.
Read clinical reviewA detailed comparison of Jardiance (empagliflozin) and Metformin covering drug costs, insurance coverage, generic availability, cardiovascular outcomes, and prescribing access for type 2 diabetes.
Read clinical reviewAn evidence-based comparison of Jardiance (empagliflozin) and Metformin for type 2 diabetes, covering HbA1c reduction, cardiovascular outcomes, weight loss, and renal protection from major clinical trials.
Read clinical reviewA clinical comparison of empagliflozin (Jardiance) and metformin side effects, including GI tolerance, genital infections, cardiovascular outcomes, and weight changes from EMPA-REG OUTCOME and UKPDS 34.
Read clinical reviewA clinical guide to switching between Jardiance (empagliflozin) and metformin, covering when to switch, how to transition, expected A1C changes, side effects, and what your prescriber considers before making the change.
Read clinical reviewA detailed comparison of Jardiance (empagliflozin) and Tresiba (insulin degludec) covering cost, insurance coverage, patient assistance programs, clinical trial data, and access strategies for people with type 2 diabetes.
Read clinical reviewEvidence-based comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba) for type 2 diabetes, covering HbA1c reduction, cardiovascular outcomes, weight effects, and hypoglycemia risk from EMPA-REG OUTCOME and DEVOTE trials.
Read clinical reviewA cross-trial comparison of empagliflozin (Jardiance) and insulin degludec (Tresiba) side effects, covering hypoglycemia, genital infections, cardiovascular outcomes, and weight changes in type 2 diabetes.
Read clinical reviewA clinical comparison of Jardiance (empagliflozin) and Tresiba (insulin degludec), including when switching between them makes sense, trial evidence, and practical guidance for patients with type 2 diabetes.
Read clinical reviewA clinical comparison of side-effect profiles for Lantus (insulin glargine) and Tresiba (insulin degludec), drawing on DEVOTE, ORIGIN, SWITCH, and BEGIN trial data.
Read clinical reviewA clinical and financial comparison of insulin glargine (Lantus) and insulin degludec (Tresiba), covering efficacy, hypoglycemia risk, WAC pricing, insurance formulary placement, and patient assistance programs.
Read clinical reviewClinical comparison of insulin glargine (Lantus) and insulin degludec (Tresiba) across HbA1c reduction, hypoglycemia rates, cardiovascular outcomes, and real-world effectiveness data.
Read clinical reviewEvidence-based comparison of Lantus (insulin glargine) and Tresiba (insulin degludec), including how to switch safely, dosing equivalence, hypoglycemia risk, and clinical trial data from ORIGIN and DEVOTE.
Read clinical reviewEvidence-based comparison of metformin and insulin glargine (Lantus) for blood sugar control, including HbA1c reduction, weight effects, cardiovascular outcomes, and guideline recommendations.
Read clinical reviewA clinical comparison of metformin and Lantus (insulin glargine) side effects, including GI symptoms, hypoglycemia risk, weight changes, and long-term safety data from UKPDS 34 and ORIGIN.
Read clinical reviewClinical comparison of metformin and Lantus (insulin glargine) for blood sugar control, including when and how to switch between them, trial evidence from UKPDS 34 and ORIGIN, and practical dosing guidance.
Read clinical reviewA clinical comparison of metformin and Tresiba (insulin degludec) covering cost, insurance access, efficacy data from UKPDS 34 and DEVOTE, and practical prescribing considerations for type 2 diabetes.
Read clinical reviewA clinical comparison of metformin and Tresiba (insulin degludec) for blood sugar control, covering HbA1c reduction, weight effects, hypoglycemia risk, and guideline positioning.
Read clinical reviewA detailed comparison of metformin and Tresiba (insulin degludec) side effects, including GI tolerance, hypoglycemia risk, weight changes, and cardiovascular safety data from UKPDS 34 and DEVOTE.
Read clinical reviewA clinical comparison of metformin and Tresiba (insulin degludec), including when and how to switch between them, efficacy data from UKPDS 34 and DEVOTE, and practical guidance for patients with type 2 diabetes.
Read clinical review